Endovascular treatment of aneurysms: gene expression of neointimal cells recruited on the embolic agent and evolution with recurrence in an experimental model

J Vasc Interv Radiol. 2005 Oct;16(10):1355-63. doi: 10.1097/01.RVI.0000171693.68581.96.

Abstract

Purpose: The authors attempted to identify genes associated with healing or recurrence after embolization in an aneurysm model in which neointima formation at the neck varies according to flow zones. A better understanding of the relationship between blood flow, molecular events, and healing or recurrence may provide future avenues to improve results of endovascular treatment of aneurysms.

Methods: Bilateral carotid venous pouch aneurysms were constructed in 36 dogs and embolized with gelatin sponges. Angiography and pathological studies were performed at T0 and/or 3 weeks (n=22). Angiographic results and neointima formation were scored using a qualitative index applied to the distal (inflow) and proximal (outflow) zones of the neck. In 14 animals, mRNA expression 1 to 14 days after embolization at the proximal or distal segment of the sponge was analyzed by RT-PCR, attempting to correlate flow zones, gene expression, and neointima formation.

Results: Aneurysms recurred at 3 weeks, as shown by significantly worse angiographic scores as compared to T0 (P<.01). Neointimal scores differed at pathology, with a more complete neointima at the proximal as compared to the distal aspect of the sponge at 3 weeks (P=.027). Embolization was followed by migration of CD31+, CD14+, smooth muscle alpha-actin+ (SMA+) cells that progressively expressed metalloproteinases (MMP-9,-12,-14), but stable or lesser, retarded expression of inhibitors (TIMP1-4). Growth factors (PDGF-BB, TGF-beta1, TNF-alpha, MCP-1 and Ang-1) were expressed at increasing levels, maximal at 7 to 14 days. Differences between distal and proximal zones were limited to increased expression of MMP-2 proximally (P<.035).

Conclusion: Gene expression after embolization is compatible with patterns associated with neointima formation. The authors have not identified key factors involved in recurrence.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / genetics
  • Angiotensin I / genetics
  • Animals
  • Becaplermin
  • Cerebral Angiography
  • Chemokine CCL2 / genetics
  • Disease Models, Animal
  • Dogs
  • Embolization, Therapeutic
  • Gelatin Sponge, Absorbable / therapeutic use
  • Gene Expression / drug effects
  • Hemostatics / therapeutic use
  • Intracranial Aneurysm / diagnostic imaging
  • Intracranial Aneurysm / genetics
  • Intracranial Aneurysm / therapy*
  • Lipopolysaccharide Receptors / genetics
  • Matrix Metalloproteinases / genetics
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism
  • Neck / blood supply
  • Neck / diagnostic imaging
  • Platelet Endothelial Cell Adhesion Molecule-1 / genetics
  • Platelet-Derived Growth Factor / genetics
  • Proto-Oncogene Proteins c-sis
  • Recurrence
  • Regional Blood Flow / drug effects
  • Reverse Transcriptase Polymerase Chain Reaction
  • Time Factors
  • Tissue Inhibitor of Metalloproteinases / genetics
  • Transforming Growth Factor beta / genetics
  • Transforming Growth Factor beta1
  • Tumor Necrosis Factor-alpha / genetics
  • Tunica Intima / cytology
  • Tunica Intima / drug effects
  • Tunica Intima / metabolism
  • Vascular Surgical Procedures*

Substances

  • Actins
  • CCL2 protein, human
  • Chemokine CCL2
  • Hemostatics
  • Lipopolysaccharide Receptors
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Platelet-Derived Growth Factor
  • Proto-Oncogene Proteins c-sis
  • TGFB1 protein, human
  • Tissue Inhibitor of Metalloproteinases
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
  • Tumor Necrosis Factor-alpha
  • Becaplermin
  • Angiotensin I
  • Matrix Metalloproteinases